451PFinal analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel/depot 120mg in the CLARINET open-label extension
暂无分享,去创建一个
C. Lombard-Bohas | P. Ruszniewski | M. Pavel | G. Rindi | M. Raderer | J. Capdevila | E. Wolin | A. Phan | G. Cadiot | M. Caplin | E. Sedláčková | N. Liyanage | J. Cwikła | X. T. Thanh